Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGHT vs VTAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: SGHT 4 – 1 VTAK (1 Tie) Matrix Metrics: SGHT 5 – 3 VTAK

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -388.1% operating margin) and revenue trajectory (+25.2% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGHT vs VTAK
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.59
-2.22% 1D
Market Cap $601.9M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.05β · 45% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 32.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 64
RSI-14: 64.1 · SMA20: $9.74 · SMA50: $9.01
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21

6-Pillar Scorecard Institutional Category Breakdown (SGHT 4 – 1 VTAK)

Columns: Metric · SGHT · VTAK
1. Valuation Multiples VTAK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.4x 0.3x
2. Growth & Scale SGHT
Revenue Growth (YoY) +25.2% +380.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $88M $1.9M
Market Cap $601.9M $548,639
3. Profitability & Quality SGHT
Gross Margin 87.7% 47.7%
Operating Margin -20.2% -388.1%
Net Profit Margin -32.1% 0.0%
Return on Equity (ROE) -50.1% -111.3%
4. Balance Sheet & Cash Flow SGHT
Cash Generation (TTM) -$17M -$10M EBITDA
Cash Flow Margin -19.1% N/A
Net Cash / Leverage $35M Net Cash $4.87 Book/Sh · -111.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.7% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGHT (5) vs VTAK (3)
Institutional Metric SGHT VTAK Criterion Row Edge
Market Capitalization
Scale
$601.9M $548,639 Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.2% +380.7% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-20.2% -388.1% Higher Margin SGHT
Net Profit Margin
Profitability
-32.1% 0.0% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-50.1% -111.3% Higher ROE SGHT
52-Week Range Position
Momentum
88% ($3–$12) 1% ($0–$3) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.05β · 45% Vol 0.19β · 76% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 58.1 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$88M $1.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 47.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($35M Net Cash) -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +26.07 pp
SGHT: +1.31% · VTAK: -24.76%
3M Horizon SGHT +135.95 pp
SGHT: +55.66% · VTAK: -80.29%
6M Horizon SGHT +226.09 pp
SGHT: +142.33% · VTAK: -83.76%
1Y Horizon SGHT +113.62 pp
SGHT: +20.99% · VTAK: -92.63%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGHT Revenue VTAK Revenue SGHT Op. Margin VTAK Op. Margin Margin Leader
FY2018 N/A $10M N/A -498.0% VTAK
FY2019 N/A $10M N/A -801.9% VTAK
FY2020 $30M $0M -116.5% -13668.3% SGHT
FY2021 $50M $0M -105.2% -133027.3% SGHT
FY2022 $70M $0M -117.7% -192578.6% SGHT
FY2023 $80M $0M -70.7% -17674.0% SGHT
FY2024 $80M $0M -63.3% -2676.9% SGHT
FY2025 $80M $0M -48.0% -2581.6% SGHT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGHT BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $601.9M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGHT vs VTAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SGHT 35.1/100 SELL), SGHT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-20.2% vs. -388.1% operating margin) and revenue trajectory (+25.2% vs. +380.7% YoY). Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (BREAKOUT options phase, RSI 64.1); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SGHT cumulative revenue shifted +166.7% while VTAK shifted +0.0%. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.

VTAK screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus VTAK (-111.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 45% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.